Anti-Rh(c), "little c," isoimmunization: the role of rHuEpo in preventing late anemia.
J Pediatr Hematol Oncol
; 35(6): e269-71, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23073047
ABSTRACT
The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, "little c," occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Isoimunização Rh
/
Eritropoetina
/
Anemia
Tipo de estudo:
Risk_factors_studies
Limite:
Female
/
Humans
/
Newborn
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article